- Home
- GILD vs UBS Comparison
GILD vs UBS Comparison
Compare GILD & UBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GILD
- UBS
- Stock Information
- Founded
- GILD 1987
- UBS 1862
- Country
- GILD United States
- UBS Switzerland
- Employees
- GILD N/A
- UBS N/A
- Industry
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- UBS Major Banks
- Sector
- GILD Health Care
- UBS Finance
- Exchange
- GILD Nasdaq
- UBS Nasdaq
- Market Cap
- GILD 145.4B
- UBS 118.6B
- IPO Year
- GILD 1992
- UBS N/A
- Fundamental
- Price
- GILD $122.58
- UBS $38.37
- Analyst Decision
- GILD Buy
- UBS Buy
- Analyst Count
- GILD 22
- UBS 3
- Target Price
- GILD $120.90
- UBS N/A
- AVG Volume (30 Days)
- GILD 6.9M
- UBS 2.0M
- Earning Date
- GILD 10-30-2025
- UBS 10-29-2025
- Dividend Yield
- GILD 2.58%
- UBS 1.94%
- EPS Growth
- GILD 6514.05
- UBS 84.33
- EPS
- GILD 6.42
- UBS 2.21
- Revenue
- GILD $29,087,000,000.00
- UBS $48,193,000,000.00
- Revenue This Year
- GILD $3.05
- UBS $4.30
- Revenue Next Year
- GILD $3.29
- UBS $3.52
- P/E Ratio
- GILD $19.09
- UBS $16.60
- Revenue Growth
- GILD 2.79
- UBS 2.09
- 52 Week Low
- GILD $86.08
- UBS $25.75
- 52 Week High
- GILD $124.61
- UBS $42.57
- Technical
- Relative Strength Index (RSI)
- GILD 61.86
- UBS 44.17
- Support Level
- GILD $114.02
- UBS $37.23
- Resistance Level
- GILD $121.58
- UBS $38.43
- Average True Range (ATR)
- GILD 3.17
- UBS 0.40
- MACD
- GILD 0.07
- UBS 0.01
- Stochastic Oscillator
- GILD 80.83
- UBS 57.72
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About UBS UBS Group AG Registered
UBS is a global financial institution built around its core strength in wealth management, serving high and ultra-high-net-worth individuals. In Switzerland, it also operates as a traditional retail and commercial bank. Its investment bank and asset management divisions complement the wealth business, providing tailored solutions to UBS clients while serving third-party customers by leveraging UBS' global reach and expertise.